| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · n-3 PUFA and vitamin E · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 300 mg | 1 g | 1278 days | 2,830 |
| CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study 2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye | 6 mg | 270 mg | 3 years | 127 |
| A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement 2013 · supplemented group · Patients scheduled for on-pump cardiac surgery; age and sex not specified | 400 IU | 2 g | — | 103 |
| Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients 2016 · omega-3 fatty acids + vitamin E · Chronic hemodialysis patients; age and sex not specified | 400 IU | 1.25 g | 12 weeks | 30 |
| Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients 2016 · omega-3 fatty acids + alpha-tocopherol · Chronic hemodialysis patients; age and sex not specified | 400 IU | 1.25 g | 12 weeks | 30 |
| Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial 2018 · vitamin E-omega-3 · University students with primary dysmenorrhea | 200 IU | — | — | 25 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea | 1.5 mg | 1.08 g | 60 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea | 1.5 mg | 1.08 g | 60 days | 21 |
| The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome 2018 · omega-3 fatty acids plus vitamin E · Women with polycystic ovary syndrome (PCOS) | 400 IU | 1 g | 12 weeks | 20 |
| The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields 2022 · Vitamin E + Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis | 100 mg | 300 mg | 90 days | 19 |
| Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial 2017 · PCSO-524® · Children and adolescents aged 6–14 years with elevated ADHD symptoms, including participants with and without an ADHD diagnosis | 675 mcg | 38.4 mg | 14 weeks | 74 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 7.6 mg | 1.42 g | 12 weeks | 40 |
| The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis 2021 · OMEGA group · Adults with relapsing-remitting multiple sclerosis; mean age 38.4 years (SD 7.1) | 782 mg | 4.95 g | 2 years | 27 |
| The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment 2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment | 782 mg | 810 mg | 26 weeks | 23 |
| Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported. | 782 mg | 810 mg | 913 days | 20 |
| Effects of Supplementation with Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins, Combined with High-Intensity Functional Training, on Exercise Performance and Body Composition: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · experimental supplement group (SG) · Healthy young adult women and men, aged approximately 29 years, familiar with high-intensity functional training and with at least 6 months of similar exercise experience | 782 mg | 6.9 g | 8 weeks | 10 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 15 mg | 650 mg | 1 year | 50 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome 2017 · omega-3 fatty acids and vitamin E · Women aged 18–40 years with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 400 IU | 1 g | 12 weeks | 34 |
| The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids and vitamin E co-supplementation · Women aged 18–40 years with polycystic ovary syndrome | 400 IU | 1 g | 12 weeks | 34 |
| A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes 2016 · omega-3 fatty acids plus vitamin E group · Women with gestational diabetes who were not taking oral hypoglycemic agents | 400 IU | 1 g | 6 weeks | 30 |
| A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes 2017 · omega-3 fatty acids plus vitamin E · Women with gestational diabetes who were not taking oral hypoglycemic agents | 400 IU | 1 g | 6 weeks | 30 |
| Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids plus vitamin E · Patients with fibrocystic breast disease | 400 mg | 1 g | 12 weeks | 28 |
| Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease 2016 · Group 2 (OE) · Male patients with coronary artery disease; age range not reported | 400 IU | 4 g | 60 days | 20 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2019 · omega-3 fatty acids plus vitamin E · Patients with Parkinson's disease; age range and sex not reported | 400 IU | 1 g | 12 weeks | 20 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 72 mg | 2.45 g | 3 weeks | 12 |
| Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients 2005 · EPA group · Patients with chronic hepatitis C receiving interferon alpha-2b and ribavirin; age and sex not reported | 300 mg | 1.8 g | 24 weeks | 5 |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 205 mg | 2.1 g | 12 weeks | — |
| Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation 2011 · n-3 PUFA plus antioxidant vitamins · Either-sex patients undergoing on-pump cardiac surgery | 400 IU | 2 g | — | — |
| Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans 1997 · Menhaden oil with vitamin E · Healthy men; age not stated | 900 IU | 6.26 g | 6 weeks | — |
| Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome 2006 · test group · Patients with metabolic syndrome; age and sex not specified | 7.5 mg | 200 mg | 90 days | 36 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 30 mg | 500 mg | 90 days | 30 |
| Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study 2022 · 4Nutri group · Young, healthy participants; age range and sex not stated | 3.29 mg | 1.03 g | 3 weeks | 20 |
| Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia 2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia) | 120 mg | 1.2 g | 30 days | 16 |
| Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise 2011 · LCPUFA plus antioxidant mixture · Judoists; age and sex not reported; no diagnosed condition stated | 30 mg | 1 g | 6 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia | 75 mg | 5 g | 6 weeks | — |
| Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers 1998 · n-3 fatty acids with antioxidants · adult male smokers with hyperlipidaemia | 75 mg | 4.8 g | 6 weeks | — |
| Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione 2002 · n-3 PUFAs plus vitamin E · Patients who survived a recent myocardial infarction (<3 months) | 300 mg | — | — | — |